11/2/2020China Adopts Patent Law Amendment: A Game Changer for Innovative Drugs

10/12/2020China Sharpens Focus on Healthcare Cost Containment amid a Basket of M...

9/2/2020As MNCs Refocus on Innovative Drugs, Feel the Pulse of China's IP Land...

8/1/2020Uncertainties Persist amid Conflicting Signals as China Intensifies He...

7/1/2020Revisiting the Basis of Your China Strategy in the Post-Covid New Norm...

6/1/2020Despite Stormy Days Ahead, Pockets of Hope and Opportunity Remain

5/1/2020Strategic Considerations for Pharma MNCs in the Post-Coronavirus China

4/1/2020Be Ready for the Dire Aftermath of the Post-Outbreak China Market

2/28/2020What Are the Lessons To Be Drawn from China's New Normal and the Lates...

2/3/2020Annual Overview of the Chinese Pharmaceutical Sector 2019 and Outlook ...

1/2/2020U.S.-China Phase I Trade Deal - An Opportunity Window MNCs Must Not Mi...

12/3/2019New Round of Negotiation for NRDL Access Begins as Big Pharma Bosses L...

Page:1/1 Total number of articles:12: [First][<<] [1] [>>] [End]